SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending following reported 700% year-over-year revenue growth, fueled by recent expanded global approvals for its cancer therapies in the EU and Saudi Arabia. The community is buzzing with anticipation of a significant short squeeze and further label expansions, highlighting the immense potential of its diverse immunotherapy platform.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending due to its FDA approval of BYSANTI for bipolar I disorder and schizophrenia, a pivotal development underscored by its New Chemical Entity (NCE) status and patent protection until 2044. The community anticipates a significant re-rating and potential short squeeze, highlighting that this second recent FDA approval makes the company vastly undervalued compared to prior rejected buyout offers.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is seeing a significant downturn after its CagriSema weight-loss drug demonstrated slightly lower efficacy than a competitor in a recent trial, prompting community discussion on whether the market's reaction is an overcorrection despite NVO's strong financial position and other successful products.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera is trending following a $25 million direct offering of common stock at $5.00 per share to institutional investors, igniting community debate over whether it signals institutional confidence in the company's MST technology for AI chips and GAA architectures or represents a dilutive "rugpull".

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is surging on overwhelmingly positive Phase 2 S-OLARIS trial results for sonelokimab in axSpA, which demonstrated exceptional efficacy and potential disease-modifying effects, further bolstered by a robust financial outlook. The community is actively discussing the drug's best-in-class potential, its significant market opportunity, and a major institutional buy-in, fueling expectations for a substantial re-evaluation and potential short squeeze ahead of its Investor Day.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Arcellx ($ACLX) is surging after Gilead Sciences ($GILD) announced its acquisition for $115 per share in cash, valuing the cancer therapy developer at up to $7.8 billion. The biotech community is enthusiastically discussing the significant premium and the potential for increased M&A activity in the oncology sector.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending due to economic concerns stemming from Donald Trump's renewed imposition of global tariffs after a Supreme Court ruling, fueling community debate on market stability and intense skepticism regarding the stock's fundamental value.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's is trending after reporting Q4 earnings with strong revenue and a dividend increase, though an EPS miss has fueled community debate over its "Hungry for MORE" strategy driving market share gains against competitive and macro pressures.

20/20 Biolabs, Inc. engages in development and commercialization of proteomics product line. Its products include One Test, PAULA's Test and BioCheck Suspisious Powder Testing Kit. The company was founded by Jonathan Cohen in May 2000 and is headquartered in Gaithersburg, MD.

20/20 Biolabs Inc

Recent IPO AIDX is trending due to extreme volatility and significant community debate, with some labeling it a 'pump and dump' anticipating further declines while others expect a major bounce, all within a broader sector experiencing pressure.

GeneDx Holdings Corp. operates as a health intelligence company. It engages in healthcare with the use of its collected disease data sets. It offers exome and genome testing for diagnosis of genetic disease. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

GeneDx Holdings Corp - Ordinary Shares - Class A

GeneDx Holdings Corp

GeneDx Holdings Corp (WGS) is highly volatile following its recent strong earnings report and raised guidance, with the stock experiencing a dramatic sell-off that has ignited community debate regarding whether it is an overreaction to the company's cited sequential Q1 test volume decline or a deeper re-evaluation of its valuation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026

IceCure Medical Successfully Completes 5-Year Patient Follow Up in ICESECRET Kidney Cancer Cryoablation Study: Final Analysis Expected in Second Quarter of 2026 IceCure Medical Successfully Completes...

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation

IceCure Announces Thomas Hospital of Infirmary Health Installs ProSense, Becomes First Hospital in Alabama to Offer Breast Cancer Cryoablation IceCure Announces Thomas Hospital of Infirmary Health...

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense

IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation Procedures in Missouri with ProSense IceCure Announces Shero Imaging is First to Offer Breast Cancer Cryoablation...

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved

IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones Achieved IceCure Announces Planned Departure of CFO Following Nine Years of Service and Key Milestones...

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales

IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense Sales IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025...

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer

IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense Cryoablation for Low-Risk Breast Cancer IceCure Expected to Report Record Fourth...

IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting

IceCure's ProSense Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting IceCure's ProSense Cryoablation Featured in 4...

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes

IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes IceCure Receives Notice of Patent Allowance in China for a Novel...

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025

IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PR Newswire...

IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer

IceCure's ProSense Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer IceCure's ProSense Cryoablation System Receives...

IceCure Medical Ltd. engages in the development and marketing of therapy for the treatment of tumors. Its product, ProSense Cryoablation System, provides invasive treatment option to destroy tumors by freezing them. The company was founded in 2006 and is headquartered in Caesarea, Israel.

Current Price	$0.5712
Prev Close	$0.5796
Open	$0.60
Dividend Yield	0.00%
50-Day Moving Average	$0.6379
Beta	0.65
Avg. Volume	252,632.75
PE Ratio	-2.24

52-Week High	$1.53
52-Week Low	$0.5401
Market Capitalization	$39.24M
EPS (Annual)	-$0.2954
Price to Book	4.23
Revenue Per Employee	$45,708.33

ICCM
Icecure Medical Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ICCM News

ICCMIcecure Medical Ltd